To view a list of available clinical trials, select a type of cancer below. You will get a general overview of the trial, the trial number, and a link to clinicaltrials.gov for the most complete information.
The OHC Clinical Trials program has 27 clinical research team members who are engaged in the passionate search for innovative treatments. OHC trials are offered at five of our offices right here in the Greater Cincinnati area. This easy access to national trials offers our patients early access to the latest in leading edge treatments without having to leave the Cincinnati community.
Anal Squamous Cell Carcinoma - INCMGA 0012-303
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
Learn MoreCholangiocarcinoma - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Learn MoreUrothelial Cancer - 516-003
A Phase 2 Study of Sitravatinib in Combination with PD-L (1) Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
Learn MoreUrothelial Cancer - 42756493BLC0002
Observational, Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations.
Learn MoreUrothelial Cancer - QBGJ398-302
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations
Learn MoreUrothelial Cancer - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Learn MoreUrothelial Cancer - SGN22E-002
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Learn MoreUrothelial Cancer - BLC3001
A Phase 3, study of Erdafitinib compared with Docetaxel or Pembrolizumab in subjects with advanced urothelial cancer and selected FGFR gene aberrations
Learn MoreBrain Cancer - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Learn MoreBreast Cancer - CT7001-001
A Phase 1/2, Study of CT7001 in Combination with Fulvestrant in Patients with Metastatic or Locally Advanced Hormone-Receptor Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Learn MoreBreast Cancer - SGNTUC-016
Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)
Learn MoreFGFR mutated Breast Cancer - INCB 54828-207
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations
Learn MoreFGFR mutated Breast Cancer - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Learn MoreBreast Cancer - 3379428
Phase 1/2, trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
Learn MoreBreast Cancer - FLEX Registry
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)
Learn MoreFGFR mutated Colorectal Cancer - INCB 54828-207
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations
Learn MoreFGFR mutated Colorectal Cancer - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Learn MoreHER2+ metastatic Colorectal Cancer - ACCRU-GI-1617, SGNTUC-017
A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer
Learn MoreKRAS G12C metastatic Colorectal Cancer - 849-010
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
Learn MoreEsophageal Squamous Cell Carcinoma - CIBI308A301
A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)
Learn MoreOvarian - VS-6766-201 | GOG 3052
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer
Learn MoreOvarian, Peritoneal, Fallopian - LAE002INT2001
An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer
Learn MoreOvarian - SLS17-201
A Phase 1/2, Study of Galinpepimut-S in combination with Pembrolizumab (MK-3475) in patients with selected advanced cancers (Ward)
Learn MoreCervical, Endometrial, Ovarian - CPI-006-001
A Phase 1/1b, Multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent or in combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant plus Pembrolizumab in adult subjects with advanced cancers
Learn MoreOvarian, Peritoneal, Fallopian - IMGN853-0416
Phase 3, Study of Mirvetuximab Soravtansine vs Investigators' Choice of Chemotherapy in Platinum-Resistant, Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Learn MoreFGFR mutated solid tumor - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Learn MoreSquamous Cell Carcinoma - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Learn MoreSquamous Cell Carcinoma - CPI-006-001
A Phase 1/1b Multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent or in combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant plus Pembrolizumab in adult subjects with advanced cancers
Learn MoreGraft Versus Host Disease - INCB 39110-309
A Phase 3, Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)
Learn MoreMultiple Myeloma - 54767414MMY3021
A Randomized Study of Daratumumab Plus Lenalidomide Alone as A maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Learn MoreChronic Lymphocytic Leukemia (CLL) - CPI-006-001
A Phase 1/1b, Multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent or in combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant plus Pembrolizumab in adult subjects with advanced cancers
Learn MoreChronic Lymphocytic Leukemia (CLL) - LOXO-BTK-20020 / J2N-OX-JZNN
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Islas-Ohlmayer)
Learn MoreChronic Myeloid Leukemia (CML) - CABL001AUS04
A Phase 3b, open label, multi-center study of Asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phae with and without T315i mutation
Learn MoreMyelodysplastic Syndrome - M15-954
A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA)
Learn MoreAcute Myeloid Leukemia (AML) - PTC299-HEM-001-LEU
Phase 1b, Study of PTC299 in Relapsed/Refractory Acute Leukemias
Learn MoreAcute Myeloid Leukemia (AML) - M19-072
A Phase 3b, Single-Arm, Multicenter Open-Label Study of sponsor provided Venetoclax in Combination with Azacitidine (SOC) or Decitabine (SOC) in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy
Learn MoreNon Small Cell Lung Cancer - 849-012
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Learn MoreNon Small Cell Lung Cancer - 61186372NSC3001
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Learn MoreNon Small Cell Lung Cancer - 20381
Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)
Learn MoreNon Small Cell Lung Cancer - 73841937NSC3003
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer MARIPOSA
Learn MoreNon Small Cell Lung Cancer - CX 839 -016
A Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes in Patients with Non-Small Cell Lung Cancer Not Previously Treated for Metastatic Disease to Determine Eligibility for a Biomarker Selected Clinical Trial (KEAPSAKE Trial)
Learn MoreNon Small Cell Lung Cancer - 213403
A Randomized, Phase 2, double-blind study to evaluate the efficacy of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy in metastatic non-squamous non-small cell lung cancer
Learn MoreNon Small Cell Lung Cancer - CX-839-014 (KEAPSAKE)
A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer
Learn MoreNon Small Cell Lung Cancer - SGN35-033
A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid tumors after progression on prior PD-1 inhibitor treatment (Waterhouse)
Learn MoreNon Small Cell Lung Cancer - 20190009
A Phase 3 Multicenter, Randomized , Open Label, Active-controlled, Study of AMG 510 versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.g12C
Learn MoreNon Small Cell Lung Cancer - GO41717
A Phase 3. Double-Blinded, Placebo-controlled study of Tiragolumab, an anti-TIGIT antibody, in combination with Atezolizumab compared with Placebo in combination with Atezolizumab in patients with previously untreated locally advanced unresectable or metastatic PD-L1 selected non-small cell lung cancer
Learn MoreNon Small Cell Lung Cancer - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Learn MoreNon Small Cell Lung Cancer - BLU-667-2303
A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer
Learn MoreNon Small Cell Lung Cancer - 516-005
A Phase 3, Randomized Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
Learn MoreNon Small Cell Lung Cancer - INCB 54828-207
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations
Learn MoreNon Small Cell Lung Cancer - CPI-006-001
A Phase 1/1b, Multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent or in combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant plus Pembrolizumab in adult subjects with advanced cancers
Learn MoreNon Small Cell Lung Cancer - CA209-73L
A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer
Learn MoreNon Small Cell Lung Cancer - 2017-0758
Observational, A Prospective Observational Study Comparing the Effectiveness of Neulasta® (Pegfilgrastim) Onpro® kit to Other Physician Choice Options for Prophylaxis of Febrile Neutropenia in Subjects with Non-Myeloid Malignancies at High Risk for Febrile Neutropenia
Learn MoreNon Small Cell Lung Cancer - Brigatinib-3001
A Phase 3, Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib
Learn MoreNon Small Cell Lung Cancer - 849-007
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Learn MoreNon Small Cell Lung Cancer - BLU-667-1101
A Phase 1, Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101) RET Mutation or Rearrangement.
Learn MorePeripheral T-Cell Lymphoma - SGN35-032
A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression
Learn MorePrevious CAR-T Cell Therapy - GC-LTFU-001
Long-term follow-up protocol for subjects treated with gene-modified T-cells
Learn MoreSmall Lymphocytic Lymphoma (SLL) - LOXO-BTK-20020 / J2N-OX-JZNN
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Learn MoreMantle Cell Lymphoma - LOXO-BTK-20019
A Phase 3, Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma
Learn MoreHodgkin's Lymphoma - SGN35-015
a Phase 2, Therapeutic. Brentuximab Vedotin provided. A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults age 60 and Above
Learn MoreHodgkin's Lymphoma - SGN35-027
A Phase 2, Multi-Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma subjects
Learn MoreDiffuse Large B-Cell Lymphoma - GO41036
A Phase 1a/1b, Open-label, multicenter study evaluating the safety of Tiragolumab as a single agent and in combination with Daratumumab in patients with relapsed or refractory Multiple Myeloma, and as a single agent and in combination with Rituximab in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma
Learn MoreDiffuse Large B-Cell Lymphoma - CPI-006-001
A Phase 1/1b, Multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent or in combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant plus Pembrolizumab in adult subjects with advanced cancers
Learn MoreMyelofibrosis - PAC203
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL)
Learn MoreMyelofibrosis - M16-191
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis
Learn MoreMultiple Myeloma - 207503
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma
Learn MoreMultiple Myeloma - 20180015
A Phase 3, Randomized, Open-Label, Phase 3 Study comparing once-weekly vs Twice-weekly Carfilzomib in combination with Lenalidomide and Dexamethasone in subjects with relapsed or refractory Multiple Myeloma
Learn MoreMultiple Myeloma - GO41036
A Phase 1a/1b, Open-label, multicenter study evaluating the safety of Tiragolumab as a single agent and in combination with Daratumumab in patients with relapsed or refractory Multiple Myeloma, and as a single agent and in combination with Rituximab in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma
Learn MoreMultiple Myeloma - 54767414MMY3021
A Randomized Study of Daratumumab Plus Lenalidomide Alone as A maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Learn MoreMultiple Myeloma - 20180117
An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone (KPd).
Learn MoreMultiple Myeloma - 207495
A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone i9n Participants with Relapsed/Refractory Multiple Myeloma (Faber)
Learn MoreMetastatic Prostate Cancer - 64091742PCR3001
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer
Learn MoreMetastatic Prostate Cancer - CAPltello-281
A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency
Learn MoreMetastatic Castration-resistant Prostate Cancer - INCB 54828-207
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Learn MoreMetastatic Castration-resistant Prostate Cancer - CPI-006-001
A Phase 1/1b, Multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent or in combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant plus Pembrolizumab in adult subjects with advanced cancers
Learn MoreMetastatic Castration-resistant Prostate Cancer - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Learn MoreMetastatic Castration-sensitive Prostate Cancer - 67652000PCR3002
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Learn MoreMetastatic Castration-resistant Prostate Cancer - D361BC00001
A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency
Learn MoreMetastatic Castration-resistant Prostate Cancer - CO-338 063
A Phase 3, Therapeutic. Atezolizumab provided. A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (TRITON3).
Learn MoreMetastatic Castration-resistant Prostate Cancer - 2017-0758
Observational, A Prospective Observational Study Comparing the Effectiveness of Neulasta® (Pegfilgrastim) Onpro® kit to Other Physician Choice Options for Prophylaxis of Febrile Neutropenia in Subjects with Non-Myeloid Malignancies at High Risk for Febrile Neutropenia
Learn MoreClear Cell Renal Cell Carcinoma - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Learn MoreClear Cell Renal Cell Carcinoma - CPI-006-001
A Phase 1/1b, Multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent or in combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant plus Pembrolizumab in adult subjects with advanced cancers
Learn MoreClear Cell Renal Cell Carcinoma - GU-MK-6482-005
A Phase 3, Open-label, Randomized Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies
Learn MoreMetastatic Cutaneous Melanoma - SGN35-033
A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid tumors after progression on prior PD-1 inhibitor treatment
Learn MoreBasal Cell Carcinoma - CX-4945-07
A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma
Learn MoreAdvanced and unresectable or metastatic solid malignancy (various mutations) - BO41932
Tumor-agnostic precision immuno-oncology and somatic targeting rational for you (TAPISTRY) phase II platform trial
Learn MoreAdvanced and unresectable or metastatic solid malignancy (HER2 alterations) - SGNTUC-019
A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Learn MoreSolid Tumor with KRAS G12C Mutation - 849-001
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Learn More